Ibogaine is a compound from the West African shrub Tabernanthe iboga that is studied for opioid and other substance-use disorders; it carries an early benefit signal and a documented risk of sudden death. Small open-label studies report that a single dose sharply reduces opioid withdrawal and craving, and in some people interrupts use for months; the strongest recent work is a 2024 Stanford study in veterans. The evidence is preliminary and uncontrolled, with no randomized trial yet. Against that signal sits a cardiac hazard: ibogaine prolongs the QT interval of the heartbeat and has caused fatal cardiac arrhythmias, with deaths recorded within hours to days of taking it.
It is Schedule I in the United States and is used mainly in unregulated overseas clinics. This page is education about what the research shows, where the law stands, and why the cardiac risk is central. It carries no dosing and no sourcing, and it is not a guide to obtaining or using it.
Findings & Outcomes
What It Is
Ibogaine is a single compound, a monoterpene indole alkaloid, extracted from the root bark of Tabernanthe iboga, a shrub used ceremonially in West Central Africa. Outside that setting it is studied for one main purpose: interrupting addiction, above all opioid dependence. A single large dose is reported to lift withdrawal and lower craving over the following days, which is different from a maintenance medication taken every day.
Two facts define this page and neither can be left out. There is an early, repeated signal that ibogaine helps people who have not been helped by other treatments. There is also a documented risk of sudden death from a disturbed heart rhythm. This page is education about both. It carries no dosing and no sourcing.
What It Does
The efficacy evidence is graded claim by claim below, and it is all one grade of evidence: small, open-label, and without a control group. In an observational study of 30 people with opioid dependence, withdrawal scores fell from 31.0 to 14.0 on a 0 to 64 scale within about three days of a single dose, and at one month half reported no opioid use in the previous 30 days, with drug-use severity still improved out to 12 months though below the one-month peak.
A separate 12-month study of 14 people treated legally in New Zealand found reduced opioid use and lower depression scores a year later, and one of the 14 died during treatment. The most rigorous recent work comes from Stanford: in 30 male Special Operations veterans with mostly mild brain injury, a single magnesium-ibogaine treatment was followed a month later by large improvements in functioning, post-traumatic stress, depression, and anxiety, with magnesium given to blunt the cardiac risk.
Those numbers describe people who did well, and they read as encouraging. What holds them back is the design, not the direction. None of these studies had a comparison group, no one was blinded, everyone chose and often paid to be there, and each was small. That combination inflates any apparent benefit and cannot separate the drug from expectation, from the detoxification care given alongside it, or from the natural course of withdrawal. No adequate randomized controlled trial has been completed. The field's own reviews describe the results as preliminary and call for controlled trials.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
How it works
Iboga alkaloids block the hERG potassium channel, the mechanism behind the QT prolongation
Ibogaine and its relatives block a specific heart channel called hERG, which is the biological reason the drug disturbs heart rhythm.
In cell studies, ibogaine and related iboga alkaloids block the hERG potassium channel that repolarizes the heart. Losing that current lengthens the QT interval and creates the electrical substrate on which a dangerous rhythm can start. Measured in: hERG channels expressed in cell systems. Mechanistic cell work explains how the risk arises but does not by itself predict the dose or the person in whom a dangerous rhythm will occur.
The study · 1
Alper et al., hERG blockade by iboga alkaloids · Cardiovasc Toxicol 2016;16(1):14-22
Addiction
Opioid withdrawal scores fell by more than half within three days, and half the group reported no opioid use a month later
In 30 people with opioid dependence, withdrawal symptoms dropped by more than half within three days of a single ibogaine dose, and one month later half reported no opioid use, but there was no comparison group.
In an observational study of 30 adults with opioid dependence, Subjective Opioid Withdrawal Scale scores fell from 31.0 to 14.0 on a 0 to 64 scale within about 76 hours of a single ibogaine dose, and at one month 15 of 30 (50%) reported no opioid use in the previous 30 days, with drug-use severity still improved from 3 to 12 months though below the one-month peak. Measured in: 30 adults with DSM-IV opioid dependence (25 men, 5 women) treated at a clinic in Mexico. What could explain it instead: Self-selection into a private overseas clinic, no comparison group, and concurrent detoxification and aftercare all sit between the drug and the outcome.. One group with no control and no blinding, in 30 self-selected patients, so the change cannot be separated from concurrent detoxification care, expectation, or the natural course of withdrawal.
The study · 1
Brown & Alper, treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes · Am J Drug Alcohol Abuse 2018;44(1):24-36
A single treatment tracked with reduced opioid use and lower depression scores held over 12 months, and one participant died during treatment
Among 14 people treated legally in New Zealand, opioid use and depression scores were lower a year after a single ibogaine treatment, but only 8 finished the study and one person died during treatment.
Among 14 New Zealanders given legal ibogaine for opioid dependence, drug-use severity on the Addiction Severity Index-Lite fell significantly from baseline to 12 months in the 8 who completed all interviews (p = 0.002), depression on the BDI-II also fell (p < 0.001), and withdrawal scores dropped acutely after treatment across all 14 (p = 0.015). One of the 14 died during treatment. Measured in: 14 adults with opioid dependence (50% female) treated legally in New Zealand. What could explain it instead: No comparison group, heavy dropout, self-selection, and treatment providers working alongside other health professionals mean the reduction cannot be attributed to ibogaine alone.. Only 8 of 14 completed follow-up, there was no control group, and one participant died during treatment, so the benefit and the hazard both come out of the same small series.
The study · 1
Noller et al., ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study · Am J Drug Alcohol Abuse 2018;44(1):37-46
Mood & stress
In veterans with brain injury, functioning, PTSD, depression and anxiety improved a month after magnesium-ibogaine
Thirty male veterans with brain injuries had large improvements in functioning, PTSD, depression and anxiety a month after a single magnesium-ibogaine treatment, but there was no control group and everyone knew they got the drug.
In 30 male Special Operations veterans with predominantly mild traumatic brain injury, disability scores improved one month after a single magnesium-ibogaine treatment (Cohen's d = 2.20), alongside large reductions in PTSD (d = 2.54), depression (d = 2.80) and anxiety (d = 2.13). Magnesium was co-administered to blunt the cardiac risk, and no serious adverse events were reported. Measured in: 30 male Special Operations Forces veterans with predominantly mild TBI (Stanford MISTIC protocol). What could explain it instead: No comparison group, self-selected veterans who traveled abroad for treatment, complementary therapies given alongside the drug, and investigator financial interests all bear on the result.. Open-label, no control group, delivered with other therapies, and run by a team holding related patents, so the very large effect sizes are provisional and unblinded.
Who this may not transfer to:Measured only in male Special Operations veterans. It has not been tested in women, and injury type, cardiac risk and hormonal factors differ by sex, so whether the same effect holds in women is unknown.
The study · 1
Cherian et al., magnesium-ibogaine therapy in veterans with traumatic brain injuries · Nat Med 2024;30(2):373-381
Evidence And Methods
No adequate randomized controlled trial has tested ibogaine for addiction; the efficacy evidence is open-label and uncontrolled
There is no proper randomized trial of ibogaine for addiction yet; all the encouraging results come from studies where everyone knew they were getting the drug and there was no comparison group.
As of 2024, the human efficacy evidence for ibogaine in substance-use disorder comes from open-label and observational studies with no blinding and no control group. No adequate randomized controlled trial has been completed, and the field's own reviews call the findings preliminary and in need of controlled trials. Measured in: the published human literature on ibogaine for substance-use disorder. Without a randomized control group the size of any true effect is unknown, and expectation and the natural course of addiction cannot be separated from the drug.
The study · 1
Cherian et al., psychedelic therapy: a primer for primary care clinicians, ibogaine · Am J Ther 2024;31(2):e133-e140
The cardiac risk is not theoretical.
A review of all known fatalities outside West Central Africa from 1990 to 2008 found 19 people who died within 1.5 to 76 hours of taking ibogaine, most of them with preexisting heart disease or other drugs also present.
The mechanism behind those deaths is understood, and it is covered in the section below.
How It Works
Ibogaine acts on several systems at once rather than through one clean target, which is part of why its mechanism is described as unusual. It binds serotonin and opioid receptors, NMDA glutamate receptors, sigma receptors, and nicotinic receptors, and the body converts it into a long-lived metabolite, noribogaine, that lingers for days and carries much of the drug's continuing activity. No single one of these actions has been shown to be the reason it lowers craving. The addiction signal and the mechanism behind it are still being worked out.
The cardiac action, in contrast, is well characterized. Ibogaine and its metabolite block the hERG potassium channel, the current that returns each heart cell to rest after a beat. When that current is cut, the heart's electrical recovery time lengthens, seen on an electrocardiogram as a prolonged QT interval, and a long QT is the setting in which a chaotic, sometimes fatal rhythm called torsades de pointes can begin. The effect is dose-related and made worse by anything that already stresses the heart or lowers potassium or magnesium, which is the reasoning behind the magnesium co-administered in the Stanford protocol.
What Happens in the Body
1The acute experience
A large dose produces many hours of a dreamlike, waking state, often with vivid imagery, over roughly a day, followed by a long period of reduced sleep. This is the window in which withdrawal is reported to ease. It also overlaps the window in which the dangerous heart-rhythm changes occur, which is why the research settings that use it keep a person on continuous cardiac monitoring.
2The lingering metabolite
The liver converts ibogaine into noribogaine, which stays in the body for days. This long tail is thought to carry part of any lasting effect on craving, and it also means the hERG-blocking action, and the QT prolongation that comes with it, does not end when the acute experience does.
3The heart under load
Blocking the hERG channel lengthens the QT interval. In a person with existing heart disease, low potassium or magnesium, other QT-prolonging drugs on board, or a large or repeated dose, that lengthening is where a fatal arrhythmia can start. This is the single most important fact on the page.
The Legal Position
Ibogaine is Schedule I in the United States, the most restricted category, so its use outside authorized research is illegal. It is not an approved treatment anywhere in the United States. Most of the human experience with it comes from clinics in Mexico, in parts of Central America and the Caribbean, and in a few other countries, which operate with little or no medical regulation and vary widely in whether they screen the heart or monitor it during treatment. New Zealand is unusual in permitting it under a controlled arrangement, which is why one of the better follow-up studies could be done there. None of this page is a route to obtaining ibogaine. It is a description of where the law and the treatment currently stand.
Go Deeper
- Psychedelics in mental health: the wider picture of psilocybin, MDMA, and the approved drug esketamine, where the trial evidence is stronger and the risks are different, and where ibogaine sits as the most cardiac-dangerous member of the group.
- Meditation and mindfulness: a low-risk way to work with a distressed or craving mind that you can start on your own, and the grounding practice the Chinese medicine view points to first.
- Purpose and meaning: the sense of direction that recovery from addiction leans on, approached as a practice in its own right.
The Chinese Medicine View
Chinese medicine has no concept of ibogaine and made no prediction about it. What the tradition does have is a long-standing frame for intense altered states and for the pull of substances, and that frame leans toward caution. The Heart is said to house the Shen, the spirit or consciousness, and clear thought, steady emotion, and settled sleep are read as signs of a rooted Shen. A mind thrown into a flood of imagery, disoriented, or agitated is described as a disturbance of the Shen, and the classical instinct is to calm and anchor such a state, not to provoke it.
Read through that lens, a long and overwhelming drug experience is not a neutral event. It could be seen as forcibly stirring the Shen, which the tradition would approach with great care, especially in someone already depleted by years of addiction, and especially where the Heart itself is the organ carrying the physical risk. Addiction, in this frame, is often understood as an empty state that a person tries to fill, and the classical response is to nourish and root rather than to storm. This is an interpretation offered in the tradition's own language, not a verdict on the research, and the wider preventive tradition of Yang Sheng, nourishing life, would put grounding practices and steady support first.
Cautions For This Practice
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Ibogaine has been followed by fatal heart-rhythm disturbances; a review found 19 deaths soon after taking it
A systematic review of all known fatalities outside West Central Africa from 1990 to 2008 found 19 people (15 men, 4 women, aged 24 to 54) who died within 1.5 to 76 hours of taking ibogaine. Preexisting medical conditions, mainly cardiovascular, and/or one or more abused drugs explained or contributed to death in 12 of the 14 cases with adequate postmortem data. A case series counts deaths without a denominator, so it cannot give a rate, but it establishes that fatal outcomes occur, most often when heart disease or other drugs are present.Alper et al., fatalities temporally associated with the ingestion of ibogaine
Ibogaine prolongs the QT interval and can trigger life-threatening heart-rhythm disturbances
A review of ibogaine's cardiac effects reports that it prolongs the QT interval and has been linked to accumulating reports of life-threatening arrhythmia and sudden death, an effect traced to block of the cardiac hERG potassium channel, with the long-lived metabolite noribogaine carrying the same action. A narrative review gathers existing reports rather than testing risk in a defined group, so it describes the hazard without quantifying how often it occurs.Koenig & Hilber, the anti-addiction drug ibogaine and the heart: a delicate relation
This is a drug that has killed people, and this is not a guide to using it
Ibogaine prolongs the QT interval and has caused fatal cardiac arrhythmias. A review of deaths found 19 people who died within hours to a few days of taking it, most with heart disease or other drugs present. Anyone with a heart condition, a long-QT tendency, low potassium or magnesium, or other QT-prolonging medication is at serious risk. This page carries no dosing, no sourcing, and no instructions for use.
The interactions that raise the danger
The cardiac risk climbs when ibogaine is combined with other drugs that prolong the QT interval, including some antidepressants, antipsychotics, and antibiotics, and when potassium or magnesium is low. Because ibogaine also acts on serotonin and opioid systems, combining it with opioids or serotonergic medication carries its own hazards. Anyone on medication is in territory where these interactions have caused deaths.
The evidence is a signal, not a settled treatment
The results that draw people to ibogaine come from small studies with no control group and no blinding, so the true size of the benefit is unknown. If addiction is the reason you are reading this, the productive step is a conversation with an addiction clinician about treatments with a settled evidence base, including trials you may be eligible for.
Ibogaine shows an early signal for a problem that current treatments often fail, and it carries a documented risk of sudden cardiac death. The stance here is to inform: read the signal at its true, preliminary strength, take the cardiac risk as the central fact, and, for anything touching your own care, talk it through with a qualified clinician.
Common Questions
Does ibogaine work for opioid addiction?
There is an early, preliminary signal that it helps, and it has not been tested in a randomized trial. Small open-label studies report that a single dose sharply reduces opioid withdrawal and craving, and that some people stay off opioids for months. In one study of 30 people, half reported no opioid use a month later. None of these studies had a control group or blinding, and no randomized trial has been completed, so the true size of the effect is unknown and expectation cannot be separated from the drug. It is a promising and preliminary signal, not a settled treatment.
Why is ibogaine dangerous?
Because it can stop the heart. Ibogaine blocks a heart channel called hERG, which lengthens the heart's electrical recovery time, the QT interval, and a long QT is the setting in which a fatal rhythm can start. A review of fatalities found 19 people who died within hours to days of taking it, most with existing heart disease or other drugs present. The risk is highest with heart disease, with low potassium or magnesium, with other QT-prolonging drugs, and at higher doses. This is why the research settings that use it keep people on continuous cardiac monitoring.
Is ibogaine legal?
Not in the United States, where it is Schedule I and not an approved treatment. Most human use happens in unregulated clinics abroad, mainly in Mexico and parts of Central America and the Caribbean, which vary widely in whether they screen and monitor the heart. New Zealand permits it under a controlled arrangement. This page describes where the law stands and is not a way to obtain anything.
What is the Stanford veterans study, and does it change the picture?
It is the most rigorous recent work, and it is still preliminary. Stanford researchers treated 30 male Special Operations veterans who had traumatic brain injury with ibogaine plus magnesium, and reported large improvements in functioning, post-traumatic stress, depression, and anxiety a month later, with magnesium used to reduce the cardiac risk. It had no control group and everyone knew they got the drug, so it strengthens the case for running a proper randomized trial rather than settling the question.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 7 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 10, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.